Page last updated: 2024-10-17

citric acid, anhydrous and Diabetes Mellitus, Type 2

citric acid, anhydrous has been researched along with Diabetes Mellitus, Type 2 in 24 studies

Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.

Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Research Excerpts

ExcerptRelevanceReference
"Urinary concentrations of Citrate and Butyric Acid showed statistical significance between Type 2 DM with Post Stroke Depression (PSD) and Type 2DM without Post Stroke Depression (PSD), with chi square test values of ϰ2=11."8.12Urinary Citrate and Butyric Acid as Early Biomarkers for Diagnosing Post Stroke Depression in T2dM. ( Mp, R, 2022)
"Urinary concentrations of Citrate and Butyric Acid showed statistical significance between Type 2 DM with Post Stroke Depression (PSD) and Type 2DM without Post Stroke Depression (PSD), with chi square test values of ϰ2=11."4.12Urinary Citrate and Butyric Acid as Early Biomarkers for Diagnosing Post Stroke Depression in T2dM. ( Mp, R, 2022)
"Type 2 diabetes mellitus is prevalent especially in Gulf countries and poses serious long-term risks to patients."2.82The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain. ( Al-Saber, F; Aldosari, W; Alselaiti, M; Darwish, A; Harb, G; Kaladari, A; Khalfan, H; Khan, G; Koda, A; Kudo, S; Nakajima, M; Rehani, R; Tanaka, T, 2016)
"Nonalcoholic fatty liver disease (NAFLD) is associated with mitochondrial damage."1.91Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. ( Amjad, W; Connelly, MA; DePaoli, AM; Dullaart, RPF; Garcia, E; Gruppen, EG; Jiang, ZG; Lai, M; Shalaurova, I, 2023)
"A 59-year-old man with type 2 diabetes mellitus (without treatment two weeks before the intoxication) intentionally ingested a substantial amount of ethanol along with ~750 mL of laminate floor cleaner containing citric acid."1.40Severe lactic acidosis in a diabetic patient after ethanol abuse and floor cleaner intake. ( Beijnen, JH; Brandjes, DP; Daling, R; Hendrikx, JJ; Hooijberg, JH; Huitema, AD; Lagas, JS; Schellens, JH, 2014)
"There were 265 patients, 126 IDDM and 139 NIDDM."1.30Urine glucose testing: another look at its relevance when blood glucose monitoring is unaffordable. ( Abdulkadir, J; Feleke, Y, 1998)

Research

Studies (24)

TimeframeStudies, this research(%)All Research%
pre-19902 (8.33)18.7374
1990's3 (12.50)18.2507
2000's4 (16.67)29.6817
2010's7 (29.17)24.3611
2020's8 (33.33)2.80

Authors

AuthorsStudies
Harmacek, D1
Pruijm, M1
Burnier, M2
Muller, ME1
Ghajarzadeh-Wurzner, A1
Bonny, O2
Zanchi, A1
Britten, FL1
Lai, CT1
Geddes, DT1
Callaway, LK1
Duncan, EL1
Mp, R1
Kitamura, N1
Zhang, S3
Morel, JD1
Nagano, U1
Taworntawat, T1
Hosoda, S1
Nakamura, A1
Ogawa, Y1
Benegiamo, G1
Auwerx, J1
Tsubota, K1
Yokoyama, Y1
Watanabe, M1
Amjad, W1
Shalaurova, I1
Garcia, E1
Gruppen, EG1
Dullaart, RPF1
DePaoli, AM1
Jiang, ZG1
Lai, M1
Connelly, MA1
Perrier, J1
Nawrot, M1
Madec, AM1
Chikh, K1
Chauvin, MA1
Damblon, C1
Sabatier, J1
Thivolet, CH1
Rieusset, J1
Rautureau, GJP1
Panthu, B1
Yannasithinon, S1
Iamsaard, S1
Halim, AA1
Alsayed, B1
Embarak, S1
Yaseen, T1
Dabbous, S1
Fontaine, O1
Dueluzeau, R1
Raibaud, P1
Chabanet, C1
Popoff, MR1
Badoual, J1
Gabilan, JC1
Andremont, A1
Gómez, L1
Andrés, S1
Sánchez, J1
Alonso, JM1
Rey, J1
López, F1
Jiménez, A1
Yan, Z1
Zhou, L1
Zhao, Y3
Wang, J6
Huang, L2
Hu, K1
Liu, H4
Wang, H3
Guo, Z1
Song, Y1
Huang, H4
Yang, R1
Owen, TW1
Al-Kaysi, RO1
Bardeen, CJ1
Cheng, Q1
Wu, S1
Cheng, T1
Zhou, X1
Wang, B4
Zhang, Q4
Wu, X2
Yao, Y3
Ochiai, T1
Ishiguro, H2
Nakano, R2
Kubota, Y2
Hara, M1
Sunada, K1
Hashimoto, K1
Kajioka, J1
Fujishima, A1
Jiao, J3
Gai, QY3
Wang, W2
Zang, YP2
Niu, LL2
Fu, YJ3
Wang, X4
Yao, LP1
Qin, QP1
Wang, ZY1
Liu, J4
Aleksic Sabo, V1
Knezevic, P1
Borges-Argáez, R1
Chan-Balan, R1
Cetina-Montejo, L1
Ayora-Talavera, G1
Sansores-Peraza, P1
Gómez-Carballo, J1
Cáceres-Farfán, M1
Jang, J1
Akin, D1
Bashir, R1
Yu, Z1
Zhu, J2
Jiang, H1
He, C2
Xiao, Z1
Xu, J3
Sun, Q1
Han, D1
Lei, H1
Zhao, K2
Zhu, L1
Li, X5
Fu, H2
Wilson, BK1
Step, DL1
Maxwell, CL1
Gifford, CA1
Richards, CJ1
Krehbiel, CR1
Warner, JM1
Doerr, AJ1
Erickson, GE1
Guretzky, JA1
Rasby, RJ1
Watson, AK1
Klopfenstein, TJ1
Sun, Y4
Liu, Z3
Pham, TD1
Lee, BK1
Yang, FC1
Wu, KH1
Lin, WP1
Hu, MK1
Lin, L3
Shao, J1
Sun, M1
Xu, G1
Zhang, X6
Xu, N1
Wang, R1
Liu, S1
He, H1
Dong, X2
Yang, M2
Yang, Q1
Duan, S1
Yu, Y2
Han, J2
Zhang, C3
Chen, L2
Yang, X1
Li, W3
Wang, T2
Campbell, DA1
Gao, K1
Zager, RA1
Johnson, ACM1
Guillem, A1
Keyser, J1
Singh, B1
Steubl, D1
Schneider, MP1
Meiselbach, H1
Nadal, J1
Schmid, MC1
Saritas, T1
Krane, V1
Sommerer, C1
Baid-Agrawal, S1
Voelkl, J1
Kotsis, F1
Köttgen, A1
Eckardt, KU1
Scherberich, JE1
Li, H4
Yao, L2
Sun, L3
Zhu, Z1
Naren, N1
Zhang, XX2
Gentile, GL1
Rupert, AS1
Carrasco, LI1
Garcia, EM1
Kumar, NG1
Walsh, SW1
Jefferson, KK1
Guest, RL1
Samé Guerra, D1
Wissler, M1
Grimm, J1
Silhavy, TJ1
Lee, JH2
Yoo, JS1
Kim, Y1
Kim, JS2
Lee, EJ1
Roe, JH1
Delorme, M1
Bouchard, PA1
Simon, M1
Simard, S1
Lellouche, F1
D'Urzo, KA1
Mok, F1
D'Urzo, AD1
Koneru, B1
Lopez, G1
Farooqi, A1
Conkrite, KL1
Nguyen, TH1
Macha, SJ1
Modi, A1
Rokita, JL1
Urias, E1
Hindle, A1
Davidson, H1
Mccoy, K1
Nance, J1
Yazdani, V1
Irwin, MS1
Yang, S1
Wheeler, DA1
Maris, JM1
Diskin, SJ1
Reynolds, CP1
Abhilash, L1
Kalliyil, A1
Sheeba, V1
Hartley, AM2
Meunier, B2
Pinotsis, N1
Maréchal, A2
Xu, JY1
Genko, N1
Haraux, F1
Rich, PR1
Kamalanathan, M1
Doyle, SM1
Xu, C1
Achberger, AM1
Wade, TL1
Schwehr, K1
Santschi, PH1
Sylvan, JB1
Quigg, A1
Leong, W1
Xu, W2
Gao, S1
Zhai, X1
Wang, C2
Gilson, E1
Ye, J1
Lu, Y1
Yan, R1
Zhang, Y6
Hu, Z1
You, Q1
Cai, Q1
Yang, D1
Gu, S1
Dai, H1
Zhao, X1
Gui, C1
Gui, J1
Wu, PK1
Hong, SK1
Starenki, D1
Oshima, K1
Shao, H1
Gestwicki, JE1
Tsai, S1
Park, JI1
Wang, Y7
Zhao, R1
Gu, Z1
Dong, C2
Guo, G1
Li, L4
Barrett, HE1
Meester, EJ1
van Gaalen, K1
van der Heiden, K1
Krenning, BJ1
Beekman, FJ1
de Blois, E1
de Swart, J1
Verhagen, HJ1
Maina, T1
Nock, BA1
Norenberg, JP1
de Jong, M1
Gijsen, FJH1
Bernsen, MR1
Martínez-Milla, J1
Galán-Arriola, C1
Carnero, M1
Cobiella, J1
Pérez-Camargo, D1
Bautista-Hernández, V1
Rigol, M1
Solanes, N1
Villena-Gutierrez, R1
Lobo, M1
Mateo, J1
Vilchez-Tschischke, JP1
Salinas, B1
Cussó, L1
López, GJ1
Fuster, V1
Desco, M1
Sanchez-González, J1
Ibanez, B1
van den Berg, P1
Schweitzer, DH1
van Haard, PMM1
Geusens, PP1
van den Bergh, JP1
Zhu, X1
Huang, X2
Xu, H2
Yang, G2
Lin, Z1
Salem, HF1
Nafady, MM1
Kharshoum, RM1
Abd El-Ghafar, OA1
Farouk, HO1
Domiciano, D1
Nery, FC1
de Carvalho, PA1
Prudente, DO1
de Souza, LB1
Chalfun-Júnior, A1
Paiva, R1
Marchiori, PER1
Lu, M2
An, Z1
Jiang, J2
Li, J7
Du, S1
Zhou, H1
Cui, J1
Wu, W1
Liu, Y7
Song, J1
Lian, Q1
Uddin Ahmad, Z1
Gang, DD1
Konggidinata, MI1
Gallo, AA1
Zappi, ME1
Yang, TWW1
Johari, Y1
Burton, PR1
Earnest, A1
Shaw, K1
Hare, JL1
Brown, WA1
Kim, GA1
Han, S1
Choi, GH1
Choi, J1
Lim, YS1
Gallo, A1
Cancelli, C1
Ceron, E1
Covino, M1
Capoluongo, E1
Pocino, K1
Ianiro, G1
Cammarota, G1
Gasbarrini, A1
Montalto, M1
Somasundar, Y1
Lu, IC1
Mills, MR1
Qian, LY1
Olivares, X1
Ryabov, AD1
Collins, TJ1
Zhao, L1
Doddipatla, S1
Thomas, AM1
Nikolayev, AA1
Galimova, GR1
Azyazov, VN1
Mebel, AM1
Kaiser, RI1
Guo, S1
Yang, P1
Yu, X2
Wu, Y2
Zhang, H1
Yu, B2
Han, B1
George, MW1
Moor, MB1
Langenberg, E1
Paik, H1
Smith, EH1
Nair, HP1
Hanke, I1
Ganschow, S1
Catalan, G1
Domingo, N1
Schlom, DG1
Assefa, MK1
Wu, G2
Hayton, TW1
Becker, B1
Enikeev, D1
Netsch, C1
Gross, AJ1
Laukhtina, E1
Glybochko, P1
Rapoport, L1
Herrmann, TRW1
Taratkin, M1
Dai, W1
Shi, J2
Carreno, J1
Kloner, RA1
Pickersgill, NA1
Vetter, JM1
Kim, EH1
Cope, SJ1
Du, K1
Venkatesh, R1
Giardina, JD1
Saad, NES1
Bhayani, SB1
Figenshau, RS1
Eriksson, J1
Landfeldt, E1
Ireland, S1
Jackson, C1
Wyatt, E1
Gaudig, M1
Stancill, JS1
Happ, JT1
Broniowska, KA1
Hogg, N1
Corbett, JA1
Tang, LF1
Bi, YL1
Fan, Y2
Sun, YB1
Wang, AL1
Xiao, BH1
Wang, LF1
Qiu, SW1
Guo, SW1
Wáng, YXJ1
Sun, J2
Chu, S1
Pan, Q1
Li, D2
Zheng, S2
Ma, L1
Wang, L3
Hu, T1
Wang, F1
Han, Z1
Yin, Z1
Ge, X1
Xie, K1
Lei, P1
Dias-Santagata, D1
Lennerz, JK1
Sadow, PM1
Frazier, RP1
Govinda Raju, S1
Henry, D1
Chung, T1
Kherani, J1
Rothenberg, SM1
Wirth, LJ1
Marti, CN1
Choi, NG1
Bae, SJ1
Ni, L1
Luo, X1
Dai, T1
Yang, Y3
Lee, R1
Fleischer, AS1
Wemhoff, AP1
Ford, CR1
Kleppinger, EL1
Helms, K1
Bush, AA1
Luna-Abanto, J1
García Ruiz, L1
Laura Martinez, J1
Álvarez Larraondo, M1
Villoslada Terrones, V1
Dukic, L1
Maric, N1
Simundic, AM1
Chogtu, B1
Ommurugan, B1
Thomson, SR1
Kalthur, SG1
Benidir, M1
El Massoudi, S1
El Ghadraoui, L1
Lazraq, A1
Benjelloun, M1
Errachidi, F1
Cassar, M1
Law, AD1
Chow, ES1
Giebultowicz, JM1
Kretzschmar, D1
Salonurmi, T1
Nabil, H1
Ronkainen, J1
Hyötyläinen, T1
Hautajärvi, H1
Savolainen, MJ1
Tolonen, A1
Orešič, M1
Känsäkoski, P1
Rysä, J1
Hakkola, J1
Hukkanen, J1
Zhu, N1
Li, Y4
Du, Q1
Hao, P1
Cao, X1
Li, CX1
Zhao, S1
Luo, XM1
Feng, JX1
Gonzalez-Cotto, M1
Guo, L1
Karwan, M1
Sen, SK1
Barb, J1
Collado, CJ1
Elloumi, F1
Palmieri, EM1
Boelte, K1
Kolodgie, FD1
Finn, AV1
Biesecker, LG1
McVicar, DW1
Qu, F1
Deng, Z1
Xie, Y2
Tang, J3
Chen, Z3
Luo, W1
Xiong, D1
Zhao, D1
Fang, J1
Zhou, Z1
Niu, PP1
Song, B1
Xu, YM1
Zhang, Z2
Qiu, N1
Yin, J1
Zhang, J3
Guo, W1
Liu, M2
Liu, T2
Chen, D5
Luo, K1
He, Z2
Zheng, G1
Xu, F1
Sun, W1
Yin, F1
van Hest, JCM1
Du, L2
Shi, X1
Kang, S1
Duan, W1
Feng, J3
Qi, N1
Shen, G1
Ren, H1
Shang, Q1
Zhao, W2
Yang, Z2
Jiang, X2
Alame, M1
Cornillot, E1
Cacheux, V1
Tosato, G1
Four, M1
De Oliveira, L1
Gofflot, S1
Delvenne, P1
Turtoi, E1
Cabello-Aguilar, S1
Nishiyama, M1
Turtoi, A1
Costes-Martineau, V1
Colinge, J1
Guo, Q1
Quan, M1
Dong, J2
Bai, J1
Han, R1
Cai, Y1
Lv, YQ1
Chen, Q1
Lyu, HD1
Deng, L1
Zhou, D1
Xiao, X1
De Langhe, S1
Billadeau, DD1
Lou, Z1
Zhang, JS1
Xue, Z1
Shen, XD1
Gao, F1
Busuttil, RW1
Kupiec-Weglinski, JW1
Ji, H1
Otano, I1
Alvarez, M1
Minute, L1
Ochoa, MC1
Migueliz, I1
Molina, C1
Azpilikueta, A1
de Andrea, CE1
Etxeberria, I1
Sanmamed, MF1
Teijeira, Á1
Berraondo, P1
Melero, I1
Zhong, Z1
Xie, X1
Yu, Q1
Zhou, C1
Liu, C3
Liu, W1
Chen, W1
Yin, Y1
Li, CW1
Hsu, JL1
Zhou, Q1
Hu, B1
Fu, P1
Atyah, M1
Ma, Q2
Xu, Y1
Dong, Q1
Hung, MC1
Ren, N1
Huang, P1
Liao, R1
Chen, X3
Cao, Q1
Yuan, X1
Nie, W1
Yang, J2
Shao, B1
Ma, X1
Bi, Z1
Liang, X1
Tie, Y1
Mo, F1
Xie, D1
Wei, Y1
Wei, X2
Dokla, EME1
Fang, CS1
Chu, PC1
Chang, CS1
Abouzid, KAM1
Chen, CS1
Blaszczyk, R1
Brzezinska, J1
Dymek, B1
Stanczak, PS1
Mazurkiewicz, M1
Olczak, J1
Nowicka, J1
Dzwonek, K1
Zagozdzon, A1
Golab, J1
Golebiowski, A1
Xin, Z1
Himmelbauer, MK1
Jones, JH1
Enyedy, I1
Gilfillan, R1
Hesson, T1
King, K1
Marcotte, DJ1
Murugan, P1
Santoro, JC1
Gonzalez-Lopez de Turiso, F1
Pedron, J1
Boudot, C1
Brossas, JY1
Pinault, E1
Bourgeade-Delmas, S1
Sournia-Saquet, A1
Boutet-Robinet, E1
Destere, A1
Tronnet, A1
Bergé, J1
Bonduelle, C1
Deraeve, C1
Pratviel, G1
Stigliani, JL1
Paris, L1
Mazier, D1
Corvaisier, S1
Since, M1
Malzert-Fréon, A1
Wyllie, S1
Milne, R1
Fairlamb, AH1
Valentin, A1
Courtioux, B1
Verhaeghe, P1
Fang, X1
Gao, M1
Gao, H1
Bi, W1
Tang, H1
Cui, Y1
Zhang, L3
Fan, H1
Yu, H1
Mathison, CJN1
Chianelli, D1
Rucker, PV1
Nelson, J1
Roland, J1
Huang, Z2
Xie, YF1
Epple, R1
Bursulaya, B1
Lee, C1
Gao, MY1
Shaffer, J1
Briones, S1
Sarkisova, Y1
Galkin, A1
Li, N1
Li, C2
Hua, S1
Kasibhatla, S1
Kinyamu-Akunda, J1
Kikkawa, R1
Molteni, V1
Tellew, JE1
Jin, X1
Pang, B1
Liu, Q2
Liu, X3
Huang, Y2
Josephine Fauci, A1
Ma, Y1
Soo Lee, M1
Yuan, W1
Gao, R1
Qi, H1
Zheng, W1
Yang, F2
Chua, H1
Wang, K1
Ou, Y1
Huang, M1
Zhu, Y1
Yu, J1
Tian, J1
Zhao, M1
Hu, J1
Yao, C1
Zhang, B1
Usawachintachit, M1
Tzou, DT1
Washington, SL1
Hu, W1
Chi, T1
Sorensen, MD1
Bailey, MR1
Hsi, RS1
Cunitz, BW1
Simon, J1
Wang, YN1
Dunmire, BL1
Paun, M1
Starr, F1
Lu, W1
Evan, AP1
Harper, JD1
Han, G1
Rodrigues, AE1
Fouladvand, F1
Falahi, E1
Asbaghi, O1
Abbasnezhad, A1
Anigboro, AA1
Avwioroko, OJ1
Cholu, CO1
Sonei, A1
Fazelipour, S1
Kanaani, L1
Jahromy, MH1
Jo, K1
Hong, KB1
Suh, HJ1
Park, JH1
Shin, E1
Park, E1
Kouakou-Kouamé, CA1
N'guessan, FK1
Montet, D1
Djè, MK1
Kim, GD1
González-Fernández, D1
Pons, EDC1
Rueda, D1
Sinisterra, OT1
Murillo, E1
Scott, ME1
Koski, KG1
Shete, PB1
Gonzales, R1
Ackerman, S1
Cattamanchi, A1
Handley, MA1
Li, XX1
Xiao, SZ1
Gu, FF1
He, WP1
Ni, YX1
Han, LZ1
Heffernan, JK1
Valgepea, K1
de Souza Pinto Lemgruber, R1
Casini, I1
Plan, M1
Tappel, R1
Simpson, SD1
Köpke, M1
Nielsen, LK1
Marcellin, E1
Cen, YK1
Lin, JG1
Wang, YL1
Wang, JY1
Liu, ZQ1
Zheng, YG1
Spirk, D1
Noll, S1
Rimoldi, S1
Noll, G1
Sudano, I1
Penzhorn, BL1
Oosthuizen, MC1
Kobos, LM1
Alqatani, S1
Ferreira, CR1
Aryal, UK1
Hedrick, V1
Sobreira, TJP1
Shannahan, JH1
Gale, P1
Singhroy, DN1
MacLean, E1
Kohli, M1
Lessem, E1
Branigan, D1
England, K1
Suleiman, K1
Drain, PK1
Ruhwald, M1
Schumacher, S1
Denkinger, CM1
Waning, B1
Van Gemert, W1
Pai, M1
Myers, RK1
Bonsu, JM1
Carey, ME1
Yerys, BE1
Mollen, CJ1
Curry, AE1
Douglas, TA1
Alinezhadbalalami, N1
Balani, N1
Schmelz, EM1
Davalos, RV1
Kamaldinov, T1
Erndt-Marino, J1
Levin, M1
Kaplan, DL1
Hahn, MS1
Heidarimoghadam, R1
Farmany, A1
Lee, JJ1
Kang, J1
Park, S1
Cho, JH1
Oh, S1
Park, DJ1
Perez-Maldonado, R1
Cho, JY1
Park, IH1
Kim, HB1
Song, M1
Mfarrej, B1
Jofra, T1
Morsiani, C1
Gagliani, N1
Fousteri, G1
Battaglia, M1
Giuliano, C1
Levinger, I1
Vogrin, S1
Neil, CJ1
Allen, JD1
Lv, Y1
Yuan, R1
Cai, B1
Bahrami, B1
Chowdhury, AH1
Yang, C2
Qiao, Q1
Liu, SF1
Zhang, WH1
Kolano, L1
Knappe, D1
Volke, D1
Sträter, N1
Hoffmann, R1
Coussens, M1
Calders, P1
Lapauw, B1
Celie, B1
Banica, T1
De Wandele, I1
Pacey, V1
Malfait, F1
Rombaut, L1
Vieira, D1
Angel, S1
Honjol, Y1
Gruenheid, S1
Gbureck, U1
Harvey, E1
Merle, G1
Seo, G1
Lee, G1
Kim, MJ1
Baek, SH1
Choi, M1
Ku, KB1
Lee, CS1
Jun, S1
Park, D1
Kim, HG1
Kim, SJ1
Lee, JO1
Kim, BT1
Park, EC1
Kim, SI1
Ende, M1
Kirkkala, T1
Loitzenbauer, M1
Talla, D1
Wildner, M1
Miletich, R1
Criado, A1
Lavela, P1
Tirado, JL1
Pérez-Vicente, C1
Kang, D1
Feng, D2
Fang, Z1
Wei, F1
De Clercq, E1
Pannecouque, C1
Zhan, P1
Guo, Y1
Shen, Y1
Wang, Q2
Kawazoe, Y1
Jena, P1
Sun, Z1
Li, Z2
Liang, H1
Xu, X1
Ma, G1
Huo, X1
Church, JS1
Chace-Donahue, F1
Blum, JL1
Ratner, JR1
Zelikoff, JT1
Schwartzer, JJ1
Fiseha, T1
Tamir, Z1
Yao, W1
Wang, P1
Mi, K1
Cheng, J1
Gu, C1
Huang, J2
Sun, HB1
Xing, WQ1
Liu, XB1
Zheng, Y1
Yang, SJ1
Wang, ZF1
Liu, SL1
Ba, YF1
Zhang, RX1
Liu, BX1
Fan, CC1
Chen, PN1
Liang, GH1
Yu, YK1
Wang, HR1
Li, HM1
Li, ZX1
Lalani, SS1
Anasir, MI1
Poh, CL1
Khan, IT1
Nadeem, M1
Imran, M1
Khalique, A1
Raspini, B1
Porri, D1
De Giuseppe, R1
Chieppa, M1
Liso, M1
Cerbo, RM1
Civardi, E1
Garofoli, F1
Monti, MC1
Vacca, M1
De Angelis, M1
Cena, H1
Kong, D1
Han, X1
Zhou, Y3
Xue, H1
Zhang, W1
Ruan, Z1
Li, S2
Noer, PR1
Kjaer-Sorensen, K1
Juhl, AK1
Goldstein, A1
Ke, C1
Oxvig, C1
Duan, C1
Kong, F1
Lin, S1
Wang, Z2
Bhattacharya, R1
Mazumder, D1
Yan, X1
Ma, C1
Tang, Y1
Kong, X1
Lu, J1
Zhang, M1
Vital-Jacome, M1
Cazares-Granillo, M1
Carrillo-Reyes, J1
Buitron, G1
Jacob, SI1
Douair, I1
Maron, L1
Ménard, G1
Rusjan, P1
Sabioni, P1
Di Ciano, P1
Mansouri, E1
Boileau, I1
Laveillé, A1
Capet, M1
Duvauchelle, T1
Schwartz, JC1
Robert, P1
Le Foll, B1
Xia, Y1
Chen, S1
Luo, M1
Wu, J1
Cai, S2
He, Y2
Garbacz, P1
Misiak, M1
Jackowski, K1
Yuan, Q1
Sherrell, PC1
Chen, J2
Bi, X1
Nutho, B1
Mahalapbutr, P1
Hengphasatporn, K1
Pattaranggoon, NC1
Simanon, N1
Shigeta, Y1
Hannongbua, S1
Rungrotmongkol, T1
Caffrey, PJ1
Kher, R1
Bian, K1
Delaney, S1
Xue, J1
Wu, P1
Xu, L1
Yuan, Y1
Luo, J1
Ye, S1
Ustriyana, P1
Wei, B1
Raee, E1
Hu, Y1
Wesdemiotis, C1
Sahai, N1
Kaur, A1
Nigam, K1
Srivastava, S1
Tyagi, A1
Dang, S1
Millar, JE1
Bartnikowski, N1
Passmore, MR1
Obonyo, NG1
Malfertheiner, MV1
von Bahr, V1
Redd, MA1
See Hoe, L1
Ki, KK1
Pedersen, S1
Boyle, AJ1
Baillie, JK1
Shekar, K1
Palpant, N1
Suen, JY1
Matthay, MA1
McAuley, DF1
Fraser, JF1
Settles, JA1
Gerety, GF1
Spaepen, E1
Suico, JG1
Child, CJ1
Oh, BL1
Lee, JS1
Lee, EY1
Lee, HY1
Yu, HG1
Leslie, I1
Boos, LA1
Larkin, J1
Pickering, L1
Lima, HK1
Vogel, K1
Hampel, D1
Wagner-Gillespie, M1
Fogleman, AD1
Ferraz, SL1
O'Connor, M1
Mazzucchelli, TG1
Kajiyama, H1
Suzuki, S1
Shimbo, A1
Utsumi, F1
Yoshikawa, N1
Kikkawa, F1
Javvaji, PK1
Dhali, A1
Francis, JR1
Kolte, AP1
Roy, SC1
Selvaraju, S1
Mech, A1
Sejian, V1
DeSilva, S1
Vaidya, SS1
Mao, C1
Akhatayeva, Z1
Cheng, H1
Zhang, G1
Jiang, F1
Meng, X1
Elnour, IE1
Lan, X1
Song, E1
Rohde, S1
Antonides, CFJ1
Muslem, R1
de Woestijne, PCV1
der Meulen, MHV1
Kraemer, US1
Dalinghaus, M1
Bogers, AJJC1
Pourmand, A1
Ghassemi, M1
Sumon, K1
Amini, SB1
Hood, C1
Sikka, N1
Duan, H1
Chen, WP1
Fan, M1
Wang, WP1
Yu, L1
Tan, SJ1
Xin, S1
Wan, LJ1
Guo, YG1
Tanda, S1
Gingl, K1
Ličbinský, R1
Hegrová, J1
Goessler, W1
Li, ZL1
Zhou, YL1
Yan, W1
Luo, L1
Su, ZZ1
Fan, MZ1
Wang, SR1
Zhao, WG1
Xu, D1
Hassan, HM1
Jiang, Z1
Bachmann, KF1
Haenggi, M1
Jakob, SM1
Takala, J1
Gattinoni, L1
Berger, D1
Bentley, RF1
Vecchiarelli, E1
Banks, L1
Gonçalves, PEO1
Thomas, SG1
Goodman, JM1
Mather, K1
Boachie, R1
Anini, Y1
Panahi, S1
Anderson, GH1
Luhovyy, BL1
Nafie, MS1
Arafa, K1
Sedky, NK1
Alakhdar, AA1
Arafa, RK1
Fan, S1
Hu, H1
Liang, J1
Hu, BC1
Wen, Z1
Hu, D1
Liu, YY1
Chu, Q1
Wu, MC1
Lu, X1
Wang, D1
Hu, M1
Shen, H1
Yao, M1
Dahlgren, RA1
Vysloužil, J1
Kulich, P1
Zeman, T1
Vaculovič, T1
Tvrdoňová, M1
Mikuška, P1
Večeřa, Z1
Stráská, J1
Moravec, P1
Balcar, VJ1
Šerý, O1
Qiao, L1
Xiong, X1
Peng, X1
Zheng, J1
Duan, J1
Xiao, W1
Zhou, HY1
Sui, ZY1
Zhao, FL1
Sun, YN1
Wang, HY1
Han, BH1
Jintao, X1
Shasha, Y1
Jincai, W1
Chunyan, L1
Mengya, Y1
Yongli, S1
Rasoanirina, BNV1
Lassoued, MA1
Miladi, K1
Razafindrakoto, Z1
Chaâbane-Banaoues, R1
Ramanitrahasimbola, D1
Cornet, M1
Sfar, S1
Liang, C1
Xing, Q1
Yi, JL1
Zhang, YQ1
Li, CY1
Tang, SJ1
Gao, C1
Sun, X1
Peng, M1
Sun, XF1
Zhang, T1
Shi, JH1
Liao, CX1
Gao, WJ1
Sun, LL1
Gao, Y1
Cao, WH1
Lyu, J1
Yu, CQ1
Wang, SF1
Pang, ZC1
Cong, LM1
Dong, Z1
Wu, F1
Wu, XP1
Jiang, GH1
Wang, XJ1
Wang, BY1
Li, LM1
Pan, L1
Wan, SP1
Yi, HWL1
He, HJ1
Yong, ZP1
Shan, GL1
Weng, TT1
Yan, SQ1
Gao, GP1
Wei, C1
Tao, FB1
Shao, ZH1
Yao, T1
Dong, S1
Shi, S1
Feng, YL1
Zhang, YW1
Wang, SP1
Shi, AX1
Operario, D1
Zhang, ZH1
Zhu, XF1
Zaller, N1
Gao, P1
Sun, YH1
Zhang, HB1
Nakamura, Y1
Haraguchi, A1
Shigeno, R1
Ito, A1
Horie, I1
Kawakami, A1
Abiru, N1
Afzali, H1
Khaksari, M1
Jeddi, S1
Kashfi, K1
Abdollahifar, MA1
Ghasemi, A1
Hendrikx, JJ1
Lagas, JS1
Daling, R1
Hooijberg, JH1
Schellens, JH1
Beijnen, JH1
Brandjes, DP1
Huitema, AD1
Popov, SS1
Pashkov, AN1
Shul'gin, KK1
Al-Saber, F1
Aldosari, W1
Alselaiti, M1
Khalfan, H1
Kaladari, A1
Khan, G1
Harb, G1
Rehani, R1
Kudo, S1
Koda, A1
Tanaka, T1
Nakajima, M1
Darwish, A1
Baynes, JW1
Murray, DB1
Patterson, AD1
Bonzo, JA1
Li, F1
Krausz, KW1
Eichler, GS1
Aslam, S1
Tigno, X1
Weinstein, JN1
Hansen, BC1
Idle, JR1
Gonzalez, FJ1
Muroyama, K1
Murosaki, S1
Yamamoto, Y1
Odaka, H1
Chung, HC1
Miyoshi, M1
Monti, LD1
Setola, E1
Fragasso, G1
Camisasca, RP1
Lucotti, P1
Galluccio, E1
Origgi, A1
Margonato, A1
Piatti, P1
Jarjis, HA1
Blackburn, NA1
Redfern, JS1
Read, NW1
O'Connor, HJ1
Dixon, MF1
Grant, AC1
Sooltan, MA1
Axon, AT1
Henry, JA1
Durante, P1
Raleigh, X1
Gómez, ME1
Campos, G1
Ryder, E1
Diraison, F1
Large, V1
Brunengraber, H1
Beylot, M1
Feleke, Y1
Abdulkadir, J1
Lamey, PJ1
Murray, BM1
Eddie, SA1
Freeman, RE1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of the SGLT2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-diabetic Subjects[NCT03093103]Phase 245 participants (Actual)Interventional2017-03-16Completed
Prospective, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Subjects With Type II Diabetes[NCT02481141]53 participants (Actual)Interventional2014-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in 2 Hour Post Meal Glucose Level

Change from baseline in blood glucose levels 2 hours after breakfast (NCT02481141)
Timeframe: Baseline, Week 2, Week 4, Week 12

Interventionmg/dL (Mean)
5-ALA-SFC Through Week 2 (50 mg 2x/Day) Change From Baseline-0.2
5-ALA-SFC Through Week 4 (75 mg 2x/Day) Change From Baseline-12.9
5-ALA-SFC Through Week 12 (100 mg 2x/Day) Change From Baseline-8.5
Placebo Through Week 2 Change From Baseline-26.5
Placebo Through Week 4 Change From Baseline-18.8
Placebo Through Week 12 Change From Baseline-33.0

Change From Baseline in Body Weight

Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12

Interventionkg (Mean)
5-ALA-SFC Through Week 6 Change From Baseline-0.1
5-ALA-SFC Through Week 12 Change From Baseline-0.2
Placebo Through Week 6 Change From Baseline-0.3
Placebo Through Week 12 Change From Baseline-0.8

Change From Baseline in Fasting Blood Glucose

The objective of the current study was to investigate the safety and preliminary efficacy of doses up to 200 mg 5-ALA - SFC in a population of patients with type 2 diabetes mellitus living in Bahrain. (NCT02481141)
Timeframe: Baseline, Week 2, Week 4, Week 12

Interventionmg/dL (Mean)
5-ALA-SFC Through Week 2 (50 mg 2x/Day) Change From Baseline2.3
5-ALA-SFC Through Week 4 (75 mg 2x/Day) Change From Baseline-0.2
5-ALA-SFC Through Wk 12 (100 mg 2x/Day) Change From Baseline-3.0
Placebo Through Week 2 Change From Baseline-7.3
Placebo Through Week 4 Change From Baseline-0.8
Placebo Through Week 12 Change From Baseline-4.2

Change From Baseline in HbA1c

Change from baseline in HbA1c % (NCT02481141)
Timeframe: Baseline, Week 2, Week 4, Week 12

Interventionpercentage of HbA1c (Mean)
5-ALA-SFC Through Week 2 (50 mg 2x/Day) Change From Baseline-0.2
5-ALA-SFC Through 4 (75 mg 2x/Day) Change From Baseline-0.3
5-ALA-SFC Through 12 (100 mg 2x/Day) Change From Baseline-0.7
Placebo Through Week 2 Change From Baseline-0.5
Placebo Through Week 4 Change From Baseline-0.5
Placebo Through Week 12 Change From Baseline-0.5

Change From Baseline in HDL (Component of Lipid Profile)

Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12

Interventionmg/dL (Mean)
5-ALA-SFC Through Week 6 Change From Baseline-0.8
5-ALA-SFC Through Week 12 Change From Baseline0.5
Placebo Through Week 6 Change From Baseline-1.6
Placebo Through Week 12 Change From Baseline-1.1

Change From Baseline in Total Cholesterol (Component of Lipid Profile)

Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12

Interventionmg/dL (Mean)
5-ALA-SFC Through Week 6 Change From Baseline-5.2
5-ALA-SFC Through Week 12 Change From Baseline6.8
Placebo Through Week 6 Change From Baseline-7.6
Placebo Through Week 12 Change From Baseline-0.1

Change From Baseline in Triglycerides (Component of Lipid Profile)

Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12

Interventionmg/dL (Mean)
5-ALA-SFC Through Week 6 Change From Baseline-1.3
5-ALA-SFC Through Week 12 Change From Baseline3.2
Placebo Through Week 6 Change From Baseline4.5
Placebo Through Week 12 Change From Baseline11.9

Change From Baseline LDL (Component of Lipid Profile)

Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12

Interventionmg/dL (Mean)
5-ALA-SFC Through Week 6 Change From Baseline-2.9
5-ALA-SFC Through Week 12 Change From Baseline7.6
Placebo Through Week 6 Change From Baseline-11.8
Placebo Through Week 12 Change From Baseline-4.0

Subjects With Adverse Events as a Measure of Safety and Tolerability

The objective of the current study was to investigate the safety and preliminary efficacy of doses up to 200 mg 5-ALA - SFC in a population of patients with type 2 diabetes mellitus living in Bahrain. (NCT02481141)
Timeframe: Week 2, Week 4, Week 12

InterventionParticipants (Count of Participants)
5-ALA-SFC Through Week 2 (50 mg 2x/Day)6
5-ALA-SFC Through Week 4 (75 mg 2x/Day)8
5-ALA-SFC Through Week 12 (100 mg 2x/Day)2
Placebo Through Week 23
Placebo Through Week 41
Placebo Through Week 121

Reviews

1 review available for citric acid, anhydrous and Diabetes Mellitus, Type 2

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016

Trials

5 trials available for citric acid, anhydrous and Diabetes Mellitus, Type 2

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
A single-arm, open-label, intervention study to investigate the improvement of glucose tolerance after administration of the 5-aminolevulinic acid (5-ALA) in the patients with mitochondrial diabetes mellitus.
    Medicine, 2021, Mar-12, Volume: 100, Issue:10

    Topics: Adenosine Triphosphate; Adult; Aminolevulinic Acid; Blood Glucose; Citric Acid; Deafness; Diabetes M

2021
The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain.
    Journal of diabetes research, 2016, Volume: 2016

    Topics: Abdominal Pain; Aminolevulinic Acid; Bahrain; Blood Glucose; Citric Acid; Cough; Diabetes Mellitus,

2016
Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy.
    American journal of physiology. Endocrinology and metabolism, 2006, Volume: 290, Issue:1

    Topics: 3-Hydroxybutyric Acid; Aged; Blood Glucose; Citric Acid; Cross-Over Studies; Cyclic GMP; Diabetes Me

2006
Non-invasive tracing of liver intermediary metabolism in normal subjects and in moderately hyperglycaemic NIDDM subjects. Evidence against increased gluconeogenesis and hepatic fatty acid oxidation in NIDDM.
    Diabetologia, 1998, Volume: 41, Issue:2

    Topics: Adult; Alanine; Blood Glucose; Carbon Isotopes; Citric Acid; Citric Acid Cycle; Diabetes Mellitus, T

1998

Other Studies

19 other studies available for citric acid, anhydrous and Diabetes Mellitus, Type 2

ArticleYear
Empagliflozin Changes Urine Supersaturation by Decreasing pH and Increasing Citrate.
    Journal of the American Society of Nephrology : JASN, 2022, Volume: 33, Issue:6

    Topics: Benzhydryl Compounds; Citric Acid; Diabetes Mellitus, Type 2; Glucosides; Healthy Volunteers; Humans

2022
Is Secretory Activation Delayed in Women with Type Two Diabetes? A Pilot Study.
    Nutrients, 2022, Mar-22, Volume: 14, Issue:7

    Topics: Body Mass Index; Breast Feeding; Citric Acid; Diabetes Mellitus, Type 2; Female; Humans; Pilot Proje

2022
Urinary Citrate and Butyric Acid as Early Biomarkers for Diagnosing Post Stroke Depression in T2dM.
    The Journal of the Association of Physicians of India, 2022, Volume: 70, Issue:4

    Topics: Biomarkers; Butyric Acid; Citric Acid; Depression; Diabetes Mellitus, Type 2; Humans; Quality of Lif

2022
Sodium ferrous citrate and 5-aminolevulinic acid improve type 2 diabetes by maintaining muscle and mitochondrial health.
    Obesity (Silver Spring, Md.), 2023, Volume: 31, Issue:4

    Topics: Aminolevulinic Acid; Animals; Citric Acid; Diabetes Mellitus, Type 2; Diet, High-Fat; DNA, Mitochond

2023
Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    International journal of molecular sciences, 2023, Aug-28, Volume: 24, Issue:17

    Topics: Adult; Aged; Citrates; Citric Acid; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Humans; Live

2023
Human Pancreatic Islets React to Glucolipotoxicity by Secreting Pyruvate and Citrate.
    Nutrients, 2023, Nov-15, Volume: 15, Issue:22

    Topics: Animals; Citric Acid; Diabetes Mellitus, Type 2; Glucose; Humans; Insulin; Insulin-Secreting Cells;

2023
Alterations of morphology and phosphorylated protein expression in the seminal vesicles of diabetic mice.
    Andrologia, 2019, Volume: 51, Issue:10

    Topics: Animals; Citric Acid; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus,

2019
Acidified Nitrite Accelerates Wound Healing in Type 2 Diabetic Male Rats: A Histological and Stereological Evaluation.
    Molecules (Basel, Switzerland), 2021, Mar-26, Volume: 26, Issue:7

    Topics: Animals; Citric Acid; Collagen; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Male; Ne

2021
Severe lactic acidosis in a diabetic patient after ethanol abuse and floor cleaner intake.
    Basic & clinical pharmacology & toxicology, 2014, Volume: 115, Issue:5

    Topics: Acidosis; Acidosis, Lactic; Alcoholic Intoxication; Citric Acid; Diabetes Mellitus, Type 2; Humans;

2014
[EFFECTS OF MELATONIN ON THE ACONITATE HYDRATASE ACTIVITY, CONTENT OF LIPID PEROXIDATION PRODUCTS AND SOME NON-ENZYMATIC ANTIOXIDANTS IN THE BLOOD OF PATIENTS WITH TYPE 2 DIABETES MELLITUS COMPLICATED BY STEATOHEPATITIS].
    Eksperimental'naia i klinicheskaia farmakologiia, 2015, Volume: 78, Issue:12

    Topics: Aconitate Hydratase; Adult; Aged; alpha-Tocopherol; Antioxidants; Citric Acid; Diabetes Mellitus, Ty

2015
The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat.
    Experimental diabetes research, 2009, Volume: 2009

    Topics: Animals; Chelating Agents; Citric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Evalu

2009
Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus.
    The Journal of biological chemistry, 2011, Jun-03, Volume: 286, Issue:22

    Topics: Amino Acid Transport Systems, Neutral; Animals; Betaine; Citric Acid; Diabetes Mellitus, Experimenta

2011
Metabolomic profilings of urine and serum from high fat-fed rats via 1H NMR spectroscopy and pattern recognition.
    Applied biochemistry and biotechnology, 2013, Volume: 169, Issue:4

    Topics: 3-Hydroxybutyric Acid; Animals; Choline; Citric Acid; Creatinine; Diabetes Mellitus, Type 2; Dietary

2013
Anti-obesity effects of a mixture of thiamin, arginine, caffeine, and citric acid in non-insulin dependent diabetic KK mice.
    Journal of nutritional science and vitaminology, 2003, Volume: 49, Issue:1

    Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Arginine; Caffeine; Citric Acid; Diabetes Mellitus, Ty

2003
The effect of ispaghula (Fybogel and Metamucil) and guar gum on glucose tolerance in man.
    The British journal of nutrition, 1984, Volume: 51, Issue:3

    Topics: Adult; Aged; Bicarbonates; Blood Glucose; Citrates; Citric Acid; Diabetes Mellitus, Type 2; Dietary

1984
Fatal accidental ingestion of Clinitest in adult.
    Journal of the Royal Society of Medicine, 1984, Volume: 77, Issue:11

    Topics: Accidents, Home; Adult; Aged; Child, Preschool; Citrates; Citric Acid; Copper Sulfate; Diabetes Mell

1984
Isozyme analysis of human polymorphonuclear leukocyte phosphofructokinase from insulin resistant individuals.
    Biochemical and biophysical research communications, 1996, Aug-23, Volume: 225, Issue:3

    Topics: Adenosine Triphosphate; Case-Control Studies; Citrates; Citric Acid; Diabetes Mellitus, Type 2; Enzy

1996
Urine glucose testing: another look at its relevance when blood glucose monitoring is unaffordable.
    Ethiopian medical journal, 1998, Volume: 36, Issue:2

    Topics: Adult; Blood Glucose; Blood Glucose Self-Monitoring; Citric Acid; Copper Sulfate; Diabetes Mellitus,

1998
The secretion of parotid saliva as stimulated by 10% citric acid is not related to precipitating factors in burning mouth syndrome.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2001, Volume: 30, Issue:2

    Topics: Antidepressive Agents; Blood Chemical Analysis; Burning Mouth Syndrome; Candidiasis, Oral; Chi-Squar

2001